Kenketu Glovenin-I in November 2015. The
corticosteroid prednisolone was authorized in some EU countries for the Bullous Pemphigoid treatment.
Prominent players such as
Akari Therapeutics, Immune Pharmaceuticals, iCo Therapeutics, Regeneron Pharmaceuticals, Sanofi,
Nihon Pharmaceutical, Innate Pharma, AstraZeneca, Alkahest, Inc., Grifols, and others are involved in developing Bullous Pemphigoid therapies. These companies hold the potential to create a significant positive shift in Bullous Pemphigoid market size.
Bullous Pemphigoid pipeline possesses potential drugs in mid and late-stage developments to be approved shortly. Certain emerging therapies such as
Dupilumab, Nomacopan, Bertilimumab (iCo-008), Avdoralimab (IPH5401), Fasenra (benralizumab), AKST4290, and many others are in the clinical trials and have shown better efficacious results in Bullous Pemphigoid patients.